Analysis of Metabolic Parameters as Predictors of Risk in the RENAAL Study
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
OBJECTIVE—Metabolic factors such as glycemic control, hyperlipidemia, and hyperkalemia are important considerations in the treatment of patients with type 2 diabetes and nephropathy. In the RENAAL (Reduction of End Points in Type 2 Diabetes With the Angiotensin II Antagonist Losartan) study, losartan reduced renal outcomes in the patient population. This post hoc analysis of the RENAAL study reports the effects of losartan on selected metabolic parameters and assesses the relationship between baseline values of metabolic parameters and the primary composite end point or end-stage renal disease (ESRD). RESEARCH DESIGN AND METHODS—Glycemic control (HbA1c) and serum lipid, uric acid, and potassium levels were compared between the losartan and placebo groups over time, and baseline levels were correlated with the risk of reaching the primary composite end point (doubling of serum creatinine, ESRD, or death) or ESRD alone. RESULTS—Losartan did not adversely affect glycemic control or serum lipid levels. Losartan-treated patients had lower total (227.4 vs. 195.4 mg/dl) and LDL (142.2 vs. 111.7 mg/dl) cholesterol. Losartan was associated with a mean increase of up to 0.3 mEq/l in serum potassium levels; however, the rate of hyperkalemia-related discontinuation was similar between the placebo and losartan groups. Univariate analysis revealed that baseline total and LDL cholesterol and triglyceride levels were associated with increased risk of developing the primary composite end point. Similarly, total and LDL cholesterol were also associated with increased risk of developing ESRD. CONCLUSIONS—Overall, losartan was well tolerated by patients with type 2 diabetes and nephropathy and was associated with a favorable effect on the metabolic profile of this population.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Brenner, B. M., Cooper, M. E., de Zeeuw, D., Keane, W. F., Mitch, W. E., Parving, H.-H., Remuzzi, G., Snapinn, S. M., Zhang, Z., & Shahinfar, S. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011161 · Cited by 7,493
Self-citationLewis, E. J., Hunsicker, L. G., Clarke, W. R., Berl, T., Pohl, M. A., Lewis, J. B., Ritz, E., Atkins, R. C., Rohde, R., & Raz, I. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011303 · Cited by 5,987
The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy
Lewis, E. J., Hunsicker, L. G., Bain, R. P., & Rohde, R. D. (1993) · New England Journal of Medicine · doi:10.1056/nejm199311113292004 · Cited by 5,394
The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes
Parving, H.-H., Lehnert, H., Bröchner-Mortensen, J., Gomis, R., Andersen, S., & Arner, P. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011489 · Cited by 2,873
Franz, M. J., Bantle, J. P., Beebe, C. A., Brunzell, J. D., Chiasson, J.-L., Garg, A., Holzmeister, L. A., Hoogwerf, B., Mayer-Davis, E., Mooradian, A. D., et al. (2002) · Diabetes Care · doi:10.2337/diacare.25.1.148 · Cited by 1,165
Muntner, P., Coresh, J., Smith, J. C., Eckfeldt, J., & Klag, M. J. (2000) · Kidney International · doi:10.1046/j.1523-1755.2000.00165.x · Cited by 667
Bakris, G. L., Copley, J. B., Vicknair, N., Sadler, R., & Leurgans, S. (1996) · Kidney International · doi:10.1038/ki.1996.480 · Cited by 417
Focal and segmental glomerulosclerosis: Analogies to atherosclerosis
Diamond, J. R., & Karnovsky, M. J. (1988) · Kidney International · doi:10.1038/ki.1988.87 · Cited by 330
Effects of hypertension and dyslipidemia on the decline in renal function
Mänttäri, M., Tiula, E., Alikoski, T., & Manninen, V. (1995) · Hypertension · doi:10.1161/01.hyp.26.4.670 · Cited by 229
Hypoglycaemia associated with use of inhibitors of angiotensin converting enzyme
Herings, R. M. C., de Boer, A., Leufkens, H. G. M., Porsius, A., & Stricker, B. H. C. (1995) · The Lancet · doi:10.1016/s0140-6736(95)91988-0 · Cited by 217
Morris, A. D., Boyle, D. I., McMahon, A. D., Pearce, H., Evans, J. M. M., Newton, R. W., Jung, R. T., MacDonald, T. M., & The Darts/Memo Collaboration (1997) · Diabetes Care · doi:10.2337/diacare.20.9.1363 · Cited by 109
Cited by
Diabetic nephropathy: diagnosis, prevention, and treatment
Gross, J. L., de Azevedo, M. J., Silveiro, S. P., Canani, L. H., Caramori, M. L., & Zelmanovitz, T. (2005) · Diabetes Care · doi:10.2337/diacare.28.1.164 · Cited by 1,839
Lipid Accumulation and Chronic Kidney Disease
Gai, Z., Wang, T., Visentin, M., Kullak-Ublick, G., Fu, X., & Wang, Z. (2019) · Nutrients · doi:10.3390/nu11040722 · Cited by 421
CD36 and Na/K-ATPase-α1 Form a Proinflammatory Signaling Loop in Kidney
Kennedy, D. J., Chen, Y., Huang, W., Viterna, J., Liu, J., Westfall, K., Tian, J., Bartlett, D. J., Tang, W. H. W., Xie, Z., et al. (2013) · Hypertension · doi:10.1161/hypertensionaha.112.198770 · Cited by 101
Voulgari, C., Katsilambros, N., & Tentolouris, N. (2011) · Metabolism · doi:10.1016/j.metabol.2011.02.014 · Cited by 90
Metadata
- Authors
- Appel, G. B., Radhakrishnan, J., Avram, M. M., DeFronzo, R. A., Escobar-Jimenez, F., Campos, M. M., Burgess, E., Hille, D. A., Dickson, T. Z., Shahinfar, S., Brenner, B. M., & for the RENAAL Study Investigators
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2003-05-01
- Volume
- 26
- Issue
- 5
- Pages
- 1402-1407
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2130914564
- Cited by
- 109
- References
- 11
- FWCI
- 5.64
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.